What is Genomic Valley Biotech share price return in the past 10 years?

Data is not available for this company

What is the P/E ratio of Genomic Valley Biotech?

The latest standalone P/E ratio of Genomic Valley Biotech as of 28-Apr-2025 is 48.94.

What is the P/B ratio of Genomic Valley Biotech?

The latest standalone P/B ratio of Genomic Valley Biotech as of 28-Apr-2025 is 4.77.

What is the 52-week high and low of Genomic Valley Biotech?

The 52-week high of Genomic Valley Biotech is Rs. 108.15 and the 52-week low is Rs. 28.36.

Genomic Valley Biotech Ltd - Stock Valuation and Financial Performance

Name: Genomic Valley Biotech
Brand: Genomic Valley Biotech

BSE: 539206 | NSE: | Agriculture | Small Cap

Place order

Genomic Valley Share Price

₹62 0.00 0.00%
as on 28-Apr'25 16:59

DeciZen - make an informed investing decision on Genomic Valley

Based on:

Data

M-Cap below 100cr DeciZen not available

Genomic Valley Biotech stock performance -

PE Chart Key Ratios

P/E Ratio (SA):

48.94

Market Cap:

18.9 Cr.

52-wk low:

28.4

52-wk high:

108.2

Is Genomic Valley Biotech Ltd an attractive stock to invest in?

1. Is Genomic Valley Biotech Ltd a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Genomic Valley Biotech Ltd is a below average quality company.

2. Is Genomic Valley Biotech Ltd undervalued or overvalued?

The key valuation ratios of Genomic Valley Biotech Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

3. Is Genomic Valley Biotech Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Genomic Valley Biotech Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Genomic Valley:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
ROCE % ⓘ	0.3%	-6%	-1.3%	1.1%	4.1%	6.1%	-5.1%	0.9%	20.4%	0.5%	-
Value Creation Index ⓘ	-1.0	-1.4	-1.1	-0.9	-0.7	-0.6	-1.4	-0.9	0.5	-1.0	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	0	0.1	0.4	0.6	1	0.9	0.2	0.1	2.7	0.2	1
Sales YoY Gr.	-	266.7%	300%	34.1%	67.8%	-14.1%	-75.3%	-66.7%	3,785.7%	-93.8%	-
Adj EPS ⓘ	-0.1	-1.5	-0.1	0.1	0.8	0.9	-1.8	-1	2.7	0.1	1.3
YoY Gr.	-	NA	NA	NA	985.7%	23.7%	-294.7%	NA	NA	-98.2%	-
BVPS (₹) ⓘ	16	14.9	14.7	14.8	15.6	16.5	14.7	9.4	11.6	11.6	13
Adj Net Profit ⓘ	0	-0.5	0	0	0.2	0.3	-0.6	-0.3	0.8	0	0
Cash Flow from Ops. ⓘ	0.1	-0.7	0.4	0.9	-1	0.4	1.5	-2.1	-0.8	0	-
Debt/CF from Ops. ⓘ	8.2	-1.1	2.2	0.9	-1.4	3.4	1	0	0	0	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	21.3%	-29.7%	-6.8%	-93.8%
Adj EPS ⓘ	NA	-42%	NA	-98.2%
BVPSⓘ	-3.5%	-5.7%	-7.6%	0.4%
Share Price	-	48.2%	31.6%	112.9%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
Return on Equity % ⓘ	-0.4	-7.8	-0.8	0.5	5	5.8	-11.7	-8.2	26	0.4	10.3
Op. Profit Mgn % ⓘ	-149.5	-406.6	-6.5	17.5	42.2	65.4	-65.6	-534.8	32.4	9.3	73.2
Net Profit Mgn % ⓘ	-78.6	-410.9	-9.4	3.6	23.6	33.8	-268.7	-429.1	30.6	9.2	66.8
Debt to Equity ⓘ	0.2	0.2	0.2	0.2	0.3	0.3	0.3	0	0	0	-
Working Cap Days ⓘ	30,531	8,883	2,098	1,382	829	1,132	3,683	8,514	430	9,602	344
Cash Conv. Cycle ⓘ	0	0	25	32	40	58	193	144	86	1,244	306

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 10.30%

Sales growth is good in last 4 quarters at 175.60%

Sales growth has been subdued in last 3 years -6.80%

Net Profit has been subdued in last 3 years 0.00%

Latest Financials - Genomic Valley Biotech Ltd.

	Standalone	Consolidated
TTM EPS (₹)	1.3	-
TTM Sales (₹ Cr.)	0.6	-
BVPS (₹.) ⓘ	13	-
Reserves (₹ Cr.) ⓘ	1	-
P/BV ⓘ	4.77	-
PE ⓘ	48.94	-

From the Market
52 Week Low / High (₹)	28.36 / 108.15
All Time Low / High (₹)	8.25 / 108.15
Market Cap (₹ Cr.)	18.9
Equity (₹ Cr.)	3.1
Face Value (₹)	10
Industry PE ⓘ	34.7

Quarterly Results

Standalone Basis

Consolidated Basis

	Mar'24	YoY Gr. Rt. %	Jun'24	YoY Gr. Rt. %	Sep'24	YoY Gr. Rt. %	Dec'24	YoY Gr. Rt. %
Sales (₹ Cr.)ⓘ	0	-100	0.2	166.7	0.2	185.7	0.2	450
Adj EPS (₹) ⓘ	-0.1	-104.5	0.4	366.7	0.5	500	0.5	537.5
Op. Profit Mgn % ⓘ	0.00	-9357 bps	81.94	3618 bps	69.27	3398 bps	70.45	1148 bps
Net Profit Mgn % ⓘ	0.00	-9636 bps	81.94	3448 bps	72.20	3691 bps	70.91	1194 bps

Management X-Ray of Genomic Valley:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Genomic Valley

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

No data found!

Key Ratios of Genomic Valley

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Peer Comparison

Company Name	CMP(₹)	Change ₹(%)	Market Cap	Net Sales (₹ Cr.)	Latest EPS (₹)	Net Profit Margin %	Latest P/E	Latest P/BV
Venkys India	1,700.9	2.9 (0.2%)	Small Cap	3,738	97.1	2	17.5	1.6
Mangalam Global Ent	13.5	0.4 (2.7%)	Small Cap	1,669	0.7	1	20	2.2
Kaveri Seed	1,448.7	19.9 (1.4%)	Small Cap	1,148	59.1	23.8	24.2	4.7
Harrisons Malayalam	197.8	0.4 (0.2%)	Small Cap	488	0.1	-0.4	-	2.4
Simran Farms	182.1	1.9 (1.1%)	Small Cap	486	24.3	-0	7.4	1.7
Nath Bio-Genes	156.7	-2.4 (-1.5%)	Small Cap	333	21.9	12.1	7.3	0.5
Apis India	294.4	0 (0%)	Small Cap	316	30.2	7.2	9.8	1.2
Bombay Burmah Trdg.	1,915.8	10.3 (0.5%)	Small Cap	261	22.6	-2.1	84.4	47.3
JK Agri Genetics	352	-1.3 (-0.4%)	Small Cap	148	-21.3	-15.7	-	1.5
Mangalam Seeds	172.6	2.6 (1.5%)	Small Cap	100	8.2	13.2	20.7	2.4

Shows rows:

Prev 1 2 3 4 5 Next

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Sales	0.03	0.11	0.44	0.59	0.99	0.85	0.21	0.07	2.72	0.17
Operating Expenses ⓘ	0.08	0.55	0.54	0.49	0.57	0.29	0.34	0.45	1.84	0.15
Manufacturing Costs	0	0.13	0.01	0.01	0.11	0.05	0.02	0.07	0.01	0
Material Costs	0.01	0.07	0.10	0.05	0.05	-0.07	0.08	0	1.58	0
Employee Cost	0.03	0.13	0.25	0.34	0.27	0.18	0.09	0.14	0.15	0.04
Other Costs ⓘ	0.04	0.22	0.19	0.10	0.15	0.13	0.16	0.23	0.10	0.11
Operating Profit ⓘ	-0.05	-0.44	-0.10	0.10	0.42	0.55	-0.14	-0.38	0.88	0.02
Operating Profit Margin (%)	-149.0%	-406.0%	-23.2%	17.0%	42.2%	65.4%	-65.6%	-534.0%	32.4%	9.3%
Other Income ⓘ	0.07	0.16	0.08	0.01	0.01	0.01	0	0.08	0.04	0
Interest ⓘ	0.03	0.02	0	0	0	0.18	0.18	0.04	0	0
Depreciation ⓘ	0.01	0.05	0.04	0.08	0.19	0.18	0.19	0.08	0.01	0
Exceptional Items ⓘ	0	0	0	0.02	0	0	0	0.42	-0.26	0
Profit Before Tax ⓘ	-0.01	-0.34	-0.07	0.06	0.23	0.21	-0.50	0	0.65	0.02
Tax ⓘ	0	-0.01	0	0.02	0	-0.08	0.06	0.01	0	0
Profit After Tax	-0.01	-0.33	-0.07	0.03	0.23	0.29	-0.56	-0.01	0.65	0.02
PAT Margin (%)	-27.8%	-307.0%	-15.5%	5.7%	23.6%	33.8%	-268.0%	-13.2%	23.8%	9.2%
Adjusted EPS (₹)	0.0	-1.1	-0.2	0.1	0.8	0.9	-1.8	0.0	2.1	0.1
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Equity and Liabilities
Shareholders Fund	5.92	5.58	4.49	4.53	4.76	5.05	4.49	2.88	3.53	3.54
Share Capital ⓘ	3.05	3.05	3.05	3.05	3.05	3.05	3.05	3.05	3.05	3.05
Reserves ⓘ	2.86	2.53	1.44	1.47	1.71	1.99	1.43	-0.18	0.47	0.49
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	0.75	0.75	0.75	0.75	1.48	1.48	1.55	0	0	0
Long Term Debt	0.75	0.75	0.75	0.75	1.48	1.48	1.55	0	0	0
Short Term Debt	0	0	0	0	0	0	0	0	0	0
Trade Payables	0	0	0.01	0.01	0	0.06	0.04	0	0.61	0.60
Others Liabilities ⓘ	0.79	0.72	0.76	1.39	0.93	1.35	1.54	0.92	0.28	0.19
Total Liabilities ⓘ	7.46	7.06	6.02	6.67	7.18	7.94	7.61	3.80	4.42	4.33
Fixed Assets
Gross Block	3.19	3.25	3.75	4.32	4.70	5.02	6.60	2.57	0.48	0
Accumulated Depreciation	0.04	0.08	0.12	0.20	0.39	0.55	0.74	0.82	0.48	0
Net Fixed Assetsⓘ	3.15	3.18	3.63	4.12	4.31	4.47	5.86	1.75	0	0
CWIP ⓘ	0	0	0	0.38	0.49	0.49	0.49	0	0	0
Investmentsⓘ	0.55	0.11	0	0	0	0	0	0	0	0.02
Inventories	0	0	0.07	0.03	0.12	0.12	0	0	0	0
Trade Receivables	0	0	0	0.02	0.06	0.10	0.06	0	2.22	2.53
Cash Equivalents	0.17	0.01	0.05	0.01	0.08	0.04	0.01	0	0.04	0.01
Others Assetsⓘ	3.59	3.76	2.26	2.11	2.13	2.72	1.19	2.04	2.16	1.78
Total Assets ⓘ	7.46	7.06	6.02	6.67	7.18	7.94	7.61	3.80	4.42	4.33

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Cash Flow From Operating Activity ⓘ	0.09	-0.69	0.35	0.87	-1.04	0.44	1.48	-2.13	-0.78	-0.02
PBT ⓘ	-0.01	-0.34	-0.07	0.06	0.23	0.21	-0.50	-0.42	0.91	0.02
Adjustment ⓘ	-0.03	-0.11	-0.03	0.04	0.18	0.18	0.19	-0.26	-0.03	0
Changes in Working Capital ⓘ	0.13	-0.23	0.45	0.77	-1.45	0.06	1.8	-1.45	-1.66	-0.03
Tax Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Cash Flow From Investing Activity ⓘ	-0.65	0.53	-0.31	-0.91	0.37	-0.47	-1.58	3.67	1.52	-0.02
Capex	-0.14	-0.08	-0.50	0	0.36	-0.48	-1.58	0	1.48	0
Net Investments	-0.55	0.44	0.11	-0.94	0	0	0	5.35	0	-0.02
Others ⓘ	0.04	0.16	0.08	0.03	0.01	0	0	-1.68	0.04	0
Cash Flow From Financing Activityⓘ	0	0	0	0	0.73	0	0.07	-1.55	-0.70	0
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	0	0	0	0	0	0	0	0	0	0
Interest Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	0	0	0	0	0.73	0	0.07	-1.55	-0.70	0
Net Cash Flow ⓘ	-0.56	-0.16	0.04	-0.04	0.06	-0.04	-0.03	-0.01	0.04	-0.04

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Ratios
ROE (%)	-0.17	-7.08	-1.51	0.76	5.01	5.83	-11.73	-0.25	20.24	0.43
ROCE (%)	0.34	-5.99	-1.31	1.12	4.12	6.1	-5.14	0.93	20.35	0.45
Asset Turnover Ratio	0	0.02	0.07	0.09	0.14	0.11	0.03	0.01	0.66	0.04
PAT to CFO Conversion(x)	N/A	N/A	N/A	29	-4.52	1.52	N/A	N/A	-1.2	-1
Working Capital Days
Receivable Days	0	0	0	14	15	35	147	0	297	5,249
Inventory Days	0	0	58	32	28	52	0	0	0	0
Payable Days	0	0	19	71	44	-183	231	3,716	70	0

Genomic Valley Biotech Ltd Stock News

View All News

Genomic Valley Biotech Ltd FAQs

What is the share price of Genomic Valley?

Company share prices are keep on changing according to the market conditions. The closing price of Genomic Valley on 28-Apr-2025 16:59 is ₹62.00.

What is the market cap of Genomic Valley?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 28-Apr-2025 16:59 the market cap of Genomic Valley stood at ₹18.94.

What is the P/E ratio of Genomic Valley?

The latest P/E ratio of Genomic Valley as of 28-Apr-2025 16:59 is 48.94.

What is the P/B ratio of Genomic Valley?

The latest P/B ratio of Genomic Valley as of 28-Apr-2025 16:59 is 4.77.

What is the 52-week high and low of Genomic Valley?

The 52-week high of Genomic Valley is ₹108.2 and the 52-week low is ₹28.36.

What is the TTM revenue of Genomic Valley?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Genomic Valley is ₹0.58 ( Cr.) .

About Genomic Valley Biotech Ltd

Genomic Valley Biotech Limited (GVBL) is formed with the objective of conducting research in the field of Biotechnology (Plant & Animal) and also to undertake commercial production of Plant Tissue Cultured Plants of different species to feed the genetically improved plant market nationally as well as internationally.

Currently, the company is engaged in providing consultancy in: a. High-Tech Cultivation through Environment Controlled Poly Houses, NFT & DFT etc; and b. Organic Farming --- Open Field Cultivation using Bio-Fertilizer. The company is also trading in agricultural and horticultural products.

Business area of the company

The Company is providing consultancy in the Horticultural and Agricultural products. The company is also trading in Horticultural and Agricultural products.